Modeling combined chemotherapy and particle therapy for locally advanced pancreatic cancer

Durante, Marco; Tommasino, Francesco; Shigeru Yamada; Camphausen, Kevin; Ohri, Nitin
July 2015
Frontiers in Oncology;Jul2015, p1
Academic Journal
Pancreatic ductal adenocarcinoma is the only cancer for which deaths are predicted to increase in 2014 and beyond. Combined radiochemotherapy protocols using gemcitabine and hypofractionated X-rays are ongoing in several clinical trials. Recent results indicate that charged particle therapy substantially increases local control of resectable and unresectable pancreas cancer, as predicted from previous radiobiology studies considering the high tumor hypoxia. Combination with chemotherapy improves the overall survival (OS). We compared published data on X-ray and charged particle clinical results with or without adjuvant chemotherapy calculating the biological effective dose. We show that chemoradiotherapy with protons or carbon ions results in 1 year OS significantly higher than those obtained with other treatment schedules. Further hypofractionation using charged particles may result in improved local control and survival. A comparative clinical trial using the standard X-ray scheme vs. the best current standard with carbon ions is crucial and may open new opportunities for this deadly disease.


Related Articles

  • The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Brunner, Thomas B.; Scott-Brown, Martin // Radiation Oncology;2010, Vol. 5, p64 

    Pancreatic ductal carcinoma is one of the most lethal malignancies, but in recent years a number of positive developments have occurred in the management of pancreatic carcinoma. This article aims to give an overview of the current knowledge regarding the role of radiotherapy in the treatment of...

  • Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Gurka, Marie K.; Collins, Sean P.; Slack, Rebecca; Tse, Gary; Charabaty, Aline; Ley, Lisa; Berzcel, Liam; Siyuan Lei; Simeng Suy; Haddad, Nadim; Jha, Reena; Johnson, Colin D.; Jackson, Patrick; Marshall, John L.; Pishvaian, Michael J. // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Background: Concurrent chemoradiation is a standard option for locally advanced pancreatic cancer (LAPC). Concurrent conventional radiation with full-dose gemcitabine has significant toxicity. Stereotactic body radiation therapy (SBRT) may provide the opportunity to administer radiation in a...

  • Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Kim, Jae-Sung; Lim, Joo; Kim, Jee; Im, Seock-Ah; Chie, Eui; Hwang, Jin-Hyeok; Kim, Tae-You; Bang, Yung-Jue; Ha, Sung; Yoon, Yong // Cancer Chemotherapy & Pharmacology;Sep2012, Vol. 70 Issue 3, p381 

    Purpose: 5-FU-based concurrent chemoradiotherapy (CRT) has been the mainstay of treatment for locally advanced pancreatic cancer (LAPC) for the past decades, but the prognosis remains dismal. Methods: Patients with pathologically confirmed LAPC of the pancreas, an ECOG PS of 0-2 and no prior...

  • Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study. Hardacre, Jeffrey; Mulcahy, Mary; Small, William; Talamonti, Mark; Obel, Jennifer; Krishnamurthi, Smitha; Rocha-Lima, Caio; Safran, Howard; Lenz, Heinz-Joseph; Chiorean, E. // Journal of Gastrointestinal Surgery;Jan2013, Vol. 17 Issue 1, p94 

    Background: Despite continued investigation, limited progress has been made in the adjuvant treatment of resected pancreatic cancer. Novel or targeted therapies are needed. Methods: Multi-institutional, open-label, dose-finding, phase 2 trial evaluating the use of algenpantucel-L (NewLink...

  • Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer. Katz, Matthew; Wang, Huamin; Balachandran, Aparna; Bhosale, Priya; Crane, Christopher; Wang, Xuemei; Pisters, Peter; Lee, Jeffrey; Vauthey, Jean-Nicolas; Abdalla, Eddie; Wolff, Robert; Abbruzzese, James; Varadhachary, Gauri; Chopin-Laly, Xavier; Charnsangavej, Chusilp; Fleming, Jason // Journal of Gastrointestinal Surgery;Jan2012, Vol. 16 Issue 1, p68 

    Objectives: To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma. Methods: One hundred ninety-four patients with pancreatic adenocarcinoma who...

  • Treatment of locoregional disease: adjuvant versus neoadjuvant. Heinemann, V. // Annals of Oncology;Sep2012 Supplement 10, Vol. 23 Issue suppl_10, px141 

    The efficacy of adjuvant therapy after the resection of pancreatic adenocarcinoma has been demonstrated by several randomized studies. Postoperative treatment applied either as chemotherapy alone or in combination with chemoradiotherapy is therefore considered a recommended standard in...

  • Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. Sho, Masayuki; Akahori, Takahiro; Tanaka, Toshihiro; Kinoshita, Shoichi; Tamamoto, Tetsuro; Nomi, Takeo; Yamato, Ichiro; Hokuto, Daisuke; Yasuda, Satoshi; Kawaguchi, Chihiro; Nishiofuku, Hideyuki; Marugami, Nagaaki; Enomonoto, Yasunori; Kasai, Takahiko; Hasegawa, Masatoshi; Kichikawa, Kimihiko; Nakajima, Yoshiyuki // Journal of Hepato -- Biliary -- Pancreatic Sciences;Feb2013, Vol. 20 Issue 2, p197 

    Background/purpose: The therapeutic options available as preoperative strategies for resectable pancreatic cancer have received worldwide attention. We have recently introduced neoadjuvant chemoradiotherapy (NACRT) to achieve local control and possibly complete cure. In this study, we have...

  • Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893). Tachezy, Michael; Gebauer, Florian; Petersen, Cordula; Arnold, Dirk; Trepel, Martin; Wegscheider, Karl; Schafhausen, Phillipe; Bockhorn, Maximilian; Izbicki, Jakob Robert; Yekebas, Emre // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Median OS after surgery in curative intent for non-metastasized pancreas cancer ranges under study conditions from 17.9 months to 23.6 months. Tumor recurrence occurs locally, at distant sites (liver, peritoneum, lungs), or both. Observational and autopsy series report local...

  • Extraosseous Ewing's sarcoma of the pancreas. Bose, Prithviraj; Murugan, Paari; Gillies, Elizabeth; Holter, Jennifer // International Journal of Clinical Oncology;Aug2012, Vol. 17 Issue 4, p399 

    The Ewing's family of tumors (EFT) comprises a molecularly defined group of 'small round blue cell tumors', consisting of Ewing's sarcoma of bone (ESB), extraosseous Ewing's sarcoma (EES), peripheral primitive neuroectodermal tumor (pPNET), and Askin's tumor. Characteristic translocations that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics